세계의 전이성 골질환 시장 보고서(2025년)

Metastatic bone disease refers to the condition where cancer cells spread from their original (primary) site to the bones, causing bone weakening and symptoms such as pain, fractures, spinal cord compression, and hypercalcemia. This indicates that the cancer has progressed and is more challenging to treat.

The main treatments for metastatic bone disease include medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication involves pharmaceutical drugs used to manage symptoms, slow disease progression, or address the underlying causes of bone metastases. These treatments are applicable to cancers originating from the breast, lung, thyroid, kidney, prostate, and other sites. The various end-users of these treatments include hospitals, specialty clinics, and ambulatory surgical centers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The metastatic bone disease market research report is one of a series of new reports from The Business Research Company that provides metastatic bone disease market statistics, including the metastatic bone disease industry global market size, regional shares, competitors with metastatic bone disease market share, detailed metastatic bone disease market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic bone disease industry. These metastatic bone disease market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic bone disease market size has grown strongly in recent years. It will grow from $17.14 billion in 2024 to $18.82 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to an increased aging population, increased cancer awareness programs, growth in the demand for effective pain management therapies, high investment in drug discovery and development, and adoption of unhealthy lifestyles.

The metastatic bone disease market size is expected to see strong growth in the next few years. It will grow to $26.82 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to the increasing geriatric population, increasing focus on developing novel radiopharmaceutical drugs, reimbursement policies, creation of cutting-edge treatment, growing demand for effective pain management therapies, and rising awareness about metastatic bone disease. Major trends in the forecast period include technological developments in diagnostics, improved diagnostic techniques, novelties in therapeutic approaches, artificial intelligence and machine learning algorithms, and technological developments in the management of bone health.

The forecast of 9.3% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. oncology by increasing the cost of radiopharmaceuticals and bone-targeted agents sourced from the Netherlands and India, thereby reducing palliative care options and elevating radiation oncology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of bone cancer is expected to propel the growth of the metastatic bone disease market. Bone cancer, a malignant tumor originating in the cells of the bone, is driven by genetic factors, radiation exposure, and environmental factors such as exposure to certain chemicals. Bone cancer can lead to metastatic bone disease as cancer cells from the primary tumor spread through the bloodstream or lymphatic system, forming new tumors in other bones. For instance, in 2023, the American Cancer Society, a US-based non-profit organization, reported 3,970 new cases of bone and joint cancer, an increase from the 3,910 cases reported in 2022. Therefore, the increasing prevalence of bone cancer is driving the growth of the metastatic bone disease market.

Major companies in the metastatic bone disease market are developing targeted therapies to improve treatment outcomes. These targeted therapies help in metastatic bone disease by precisely targeting cancer cells, minimizing damage to healthy cells, and offering a personalized treatment approach based on the individual patient's molecular characteristics. For example, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, introduced Zometa (zoledronic acid), a bisphosphonate medication approved for the prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma. These advancements aim to improve treatment outcomes and quality of life for patients with metastatic bone disease.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix's therapeutic pipeline, strengthening its position in radiopharmaceutical innovation and widening its focus on oncology and rare diseases. Through this deal, Telix intends to accelerate the development and delivery of treatments for bone metastases, aiming to provide significant benefits to affected patients. QSAM Biosciences Inc. is a US-based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Major companies operating in the metastatic bone disease market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Eli Lilly and Company, Amgen Inc., Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Jazz Pharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Mylan N.V., Novocure GmbH, Galapagos NV, Telix Pharmaceuticals Limited

North America was the largest region in the metastatic bone disease market in 2024. The regions covered in the metastatic bone disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic bone disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The metastatic bone disease market consists of revenues earned by entities by providing services such as chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic bone disease market includes sales of intramedullary rods, plates and screws, prosthetic devices, spinal instrumentation, and radiation therapy accessories. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Bone Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic bone disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic bone disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metastatic bone disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Medication; Radiation Therapy; Surgical Intervention; Tumor Ablation Therapy
• 2) By Origin: Breast; Lung; Thyroid; Kidney; Prostate; Other Origins
• 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Medication: Bisphosphonates; Denosumab; Chemotherapy Drugs; Hormonal Therapies; Targeted Therapies; Radiation Therapy
• 2) By Radiation Therapy: External Beam Radiation Therapy; Internal Radiation Therapy
• 3) By Surgical Intervention: Bone Stabilization Surgery; Bone Resection Surgery; Spinal Decompression Surgery
• 4) By Tumor Ablation Therapy: Radiofrequency Ablation; Cryoablation; Microwave Ablation
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; Bayer AG; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; GSK plc; Takeda Pharmaceutical Company Limited; Medtronic plc; Eli Lilly and Company; Amgen Inc.; Boston Scientific Corporation; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Jazz Pharmaceuticals Inc.; Exelixis Inc.; BeiGene Ltd.; Mylan N.V.; Novocure GmbH; Galapagos NV; Telix Pharmaceuticals Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Bone Disease Market Characteristics

3. Metastatic Bone Disease Market Trends And Strategies

4. Metastatic Bone Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Metastatic Bone Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic Bone Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic Bone Disease Market Growth Rate Analysis
• 5.4. Global Metastatic Bone Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic Bone Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic Bone Disease Total Addressable Market (TAM)

6. Metastatic Bone Disease Market Segmentation

• 6.1. Global Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Radiation Therapy
• Surgical Intervention
• Tumor Ablation Therapy
• 6.2. Global Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast
• Lung
• Thyroid
• Kidney
• Prostate
• Other Origins
• 6.3. Global Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• 6.4. Global Metastatic Bone Disease Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Denosumab
• Chemotherapy Drugs
• Hormonal Therapies
• Targeted Therapies
• Radiation Therapy
• 6.5. Global Metastatic Bone Disease Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Internal Radiation Therapy
• 6.6. Global Metastatic Bone Disease Market, Sub-Segmentation Of Surgical Intervention, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bone Stabilization Surgery
• Bone Resection Surgery
• Spinal Decompression Surgery
• 6.7. Global Metastatic Bone Disease Market, Sub-Segmentation Of Tumor Ablation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Radiofrequency Ablation
• Cryoablation
• Microwave Ablation

7. Metastatic Bone Disease Market Regional And Country Analysis

• 7.1. Global Metastatic Bone Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic Bone Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Bone Disease Market

• 8.1. Asia-Pacific Metastatic Bone Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Bone Disease Market

• 9.1. China Metastatic Bone Disease Market Overview
• 9.2. China Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Bone Disease Market

• 10.1. India Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Bone Disease Market

• 11.1. Japan Metastatic Bone Disease Market Overview
• 11.2. Japan Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Bone Disease Market

• 12.1. Australia Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Bone Disease Market

• 13.1. Indonesia Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Bone Disease Market

• 14.1. South Korea Metastatic Bone Disease Market Overview
• 14.2. South Korea Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Bone Disease Market

• 15.1. Western Europe Metastatic Bone Disease Market Overview
• 15.2. Western Europe Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Bone Disease Market

• 16.1. UK Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Bone Disease Market

• 17.1. Germany Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Bone Disease Market

• 18.1. France Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Bone Disease Market

• 19.1. Italy Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Bone Disease Market

• 20.1. Spain Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Bone Disease Market

• 21.1. Eastern Europe Metastatic Bone Disease Market Overview
• 21.2. Eastern Europe Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Bone Disease Market

• 22.1. Russia Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Bone Disease Market

• 23.1. North America Metastatic Bone Disease Market Overview
• 23.2. North America Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Bone Disease Market

• 24.1. USA Metastatic Bone Disease Market Overview
• 24.2. USA Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Bone Disease Market

• 25.1. Canada Metastatic Bone Disease Market Overview
• 25.2. Canada Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Bone Disease Market

• 26.1. South America Metastatic Bone Disease Market Overview
• 26.2. South America Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Bone Disease Market

• 27.1. Brazil Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Bone Disease Market

• 28.1. Middle East Metastatic Bone Disease Market Overview
• 28.2. Middle East Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Bone Disease Market

• 29.1. Africa Metastatic Bone Disease Market Overview
• 29.2. Africa Metastatic Bone Disease Market, Segmentation By Treatment , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic Bone Disease Market, Segmentation By Origin , Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic Bone Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Bone Disease Market Competitive Landscape And Company Profiles

• 30.1. Metastatic Bone Disease Market Competitive Landscape
• 30.2. Metastatic Bone Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Bone Disease Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Novartis AG
• 31.5. GSK plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Medtronic plc
• 31.8. Eli Lilly and Company
• 31.9. Amgen Inc.
• 31.10. Boston Scientific Corporation
• 31.11. Regeneron Pharmaceuticals Inc.
• 31.12. Astellas Pharma Inc.
• 31.13. Daiichi Sankyo Company Limited
• 31.14. Jazz Pharmaceuticals Inc.
• 31.15. Exelixis Inc.

32. Global Metastatic Bone Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Bone Disease Market

34. Recent Developments In The Metastatic Bone Disease Market

35. Metastatic Bone Disease Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic Bone Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic Bone Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic Bone Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer